Search
Search
David S. Boyer, MD
Show Description +
David S. Boyer, MD, shares his overall impressions of the Stage 1 results of the DIAMOND Phase 3 trial in patients with DME treated with OCS-01 eye drops, and what these results could mean to shift the paradigm of current clinical practice. He furthermore discusses the safety profile of OCS-01 and what he anticipates for Stage 2 of the DIAMOND trial. He emphasizes the benefits of treating DME patients with a topical eye drop at a much earlier stage, and patients’ preference for non-invasive treatment options.
Posted: 11/14/2023
David S. Boyer, MD
David S. Boyer, MD, shares his overall impressions of the Stage 1 results of the DIAMOND Phase 3 trial in patients with DME treated with OCS-01 eye drops, and what these results could mean to shift the paradigm of current clinical practice. He furthermore discusses the safety profile of OCS-01 and what he anticipates for Stage 2 of the DIAMOND trial. He emphasizes the benefits of treating DME patients with a topical eye drop at a much earlier stage, and patients’ preference for non-invasive treatment options.
Posted: 11/14/2023
About Oculis
Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
Learn more at oculis.com
Follow Oculis
.00_06_20_16.Still002%20(2)_1699991701.png?auto=compress,format&w=180)
.00_04_26_15.Still001%20(1)_1699991782.png?auto=compress,format&w=180)
.00_04_02_05.Still001%20(1)_1699991905.png?auto=compress,format&w=180)
.00_05_09_03.Still001%20(1)_1699992346.png?auto=compress,format&w=180)